ASH 2015 Conference - Focus on Multiple Myeloma

In this Review:

Autologous SCT for MM in new-drug era
Daratumumab for heavily pretreated relapsed/refractory MM
Elotuzumab + LD in relapsed/ refractory MM
Ixazomib + LD in relapsed/refractory MM
SLAMF7-specific CAR T-cells eliminate myeloma cells
MM remission with anti-BCMA CAR T-cells
Pembrolizumab, pomalidomide, dexamethasone in relapsed/ refractory MM
LD ± bortezomib in previously untreated MM
Ibrutinib + carfilzomib in relapsed/ refractory MM
Weekly carfilzomib with dexamethasone for relapsed/ refractory MM

Please login below to download this issue (PDF)

Subscribe